CPTCF (Cytophage Technologies) Common Stock : $18.67 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Common Stock?

Cytophage Technologies's quarterly common stock declined from Mar. 2024 ($18.59 Mil) to Jun. 2024 ($18.37 Mil) but then increased from Jun. 2024 ($18.37 Mil) to Sep. 2024 ($18.67 Mil).

Cytophage Technologies's annual common stock increased from Dec. 2021 ($11.18 Mil) to Dec. 2022 ($11.37 Mil) but then declined from Dec. 2022 ($11.37 Mil) to Dec. 2023 ($3.73 Mil).

Cytophage Technologies Common Stock Historical Data

The historical data trend for Cytophage Technologies's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Common Stock Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Common Stock

11.18

11.37

3.73

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial					11.96	3.73	18.59	18.37	18.67

Cytophage Technologies Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Cytophage Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (GREY:CPTCF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CYTO:Canada

Address

26 Henlow Bay, Winnipeg, MB, CAN, R3Y 1G4

Website

https://www.cytophage.com

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.